Goldfinch Bio will receive $15M up front & is eligible to receive ~$520M in milestones for each licensed TRPC4/5 candidate from which $410M for regulatory approval & commercial sales milestones along with royalty on net sales of each licensed product
Karuna to get the global development, manufacturing & commercialization rights to Goldfinch Bio’s transient receptor potential canonical 4 and 5 (TRPC4/5) channel candidates, incl. GFB-887 for various psychiatric & neurological conditions. The development details of GFB-887 are expected in H2’23
In preclinical models of mood & anxiety disorders, GFB-887 showed compelling benefits. Karuna will use its expertise in developing therapies for psychiatric disorders to advance TRPC4/5 candidate
Ref: Globe Newswire | Image: Karuna Therapeutics
Related News:- Zai Lab Entered into an Exclusive License Agreement with Karuna Therapeutics to Develop and Commercialize KarXT (xanomeline-trospium) in Greater China
